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Abstract
Aim To describe characteristics associated with statin prescribing for the primary prevention of cardiovascular disease
in people with newly diagnosed diabetes.
Methods Data from the Scottish Care Information—Diabetes Collaboration data set for 2006–2008 were used. This
data set contains socio-demographic and prescribing data for over 99% of people with diagnosed diabetes in Scotland.
Analyses were conducted on people aged over 40 years diagnosed with Type 1 or Type 2 diabetes between 2006 and
2008 with complete data and no previous history of cardiovascular or statin prescription. Logistic regression was used to
calculate odds ratios for statin prescription in the 2 years following diagnosis of diabetes.
Results There were 7157 men and 5601 women who met the inclusion criteria, 68% of whom had a statin prescription
recorded in the 2 years following diagnosis of diabetes. The proportions receiving statins were lower above 65 years of
age in men and 75 years of age in women. People with Type 1 diabetes had lower odds of receiving statins than people
with Type 2 diabetes [odds ratio (95% CI) 0.42 (0.29–0.61) for men and 0.48 (0.28–0.81) for women, after adjustment
for age, BMI, smoking status, cholesterol level and deprivation]. Higher total cholesterol, BMI and being a current
smoker were associated with greater odds of statin prescription.
Conclusion Approximately one third of the study population had no record of statin prescription during the 2 years
after diagnosis of diabetes. Cardiovascular disease risk reduction opportunities may be missed in some of these people.
Diabet. Med. 31; 640–646 (2014)
Introduction
Diabetes mellitus is well established as a risk factor for
cardiovascular disease and it is recommended that diabetes
management should include attempts to prevent or delay the
development of cardiovascular complications [1]. Statins have
been shown to reduce the risk of cardiovascular disease in
peoplewith diabetes and have becomepart of standard care [2].
Diabetes and cardiovascular risk factors are more prevalent in
older than younger age groups, in men than women and in
deprived than affluent populations in developed countries and
various risk scores take these factors into account [3,4].
Inequitable use of effective treatments to reduce risk of
cardiovascular disease could exacerbate inequalities in health.
The presence of clinical guidelines to aid decision making
should support equitable care by recommending treatment
based upon relevant clinical factors and cost-effectiveness.
However the availability of guidelines will not necessarily
result in equitable treatment [5]. Despite this, guidelines can
be used to identify a population of people who are
recommended to receive treatment and investigate patterns
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of treatment and non-treatment within that group. Inequal-
ities have previously been demonstrated in the management
of coronary heart disease in the general population of
Scotland 6], but it is not clear whether a similar pattern exists
among people with diabetes in a contemporary population.
In recent years, statins appear to be used more widely among
deprived than affluent populations, but it is not clear whether
statin use for primary prevention of cardiovascular disease is
equitable among people with diabetes [7].
In 2005, the Joint British Societies (JBS) recommended that
statins be offered to all people with diabetes to lower
cholesterol, as the presence of diabetes alone was determined
to identify high cardiovascular disease risk requiring appropri-
ate management; in addition, the national guidelines from the
Scottish Intercollegiate Guidance Network (SIGN) indicated
that cardiovascular disease risk and consequent treatment
ought to be based upon Joint British Society recommendations
[8,9]. Associations between socio-demographic factors and
statin prescribing have been described in the general population
of Scotland and in other settings [10,11] and socio-economic
inequalities in cardiovascular disease mortality among people
with diabetes persist in Scotland [12]. The aim of this work was
to investigate the patterns of statin prescribing in people with
diabetes in Scotland, in order to establish what proportion of
people with newly diagnosed diabetes receive statins for
primary prevention of cardiovascular disease and whether
there was equitable recording of statin prescribing.
Methods
The Scottish Care Information – Diabetes Collaboration
(SCI-DC) supports a national population-based electronic
diabetes register containing clinical and demographic data
for people with diabetes that is used to support clinical care
and is updated daily [13]. Individuals are included on this
register if they are treated at either a Scottish hospital clinic
or at one of approximately 99.5% of Scottish general
practices, making the data set representative of people with
diagnosed diabetes in Scotland. Approval for linkage of a
pseudonymized Scottish Care Information – Diabetes Col-
laboration research data extract to other sources of health
data including previous hospital admissions was obtained
from the Scotland A Multi-centre research ethics committee,
Caldicott guardians of all Health Boards and the Privacy
Advisory Committee of NHS National Services Scotland.
The data set used in this study is derived from a 2008 data
extract that contains records for 272 074 people with
diagnosed diabetes with an updated linkage of subsequent
prescribing data in 2011.
Variables used
Age, sex, BMI, smoking status, total serum cholesterol and
type of diabetes (defined using an algorithm based on type
recorded in clinical records, age at diagnosis of diabetes and
treatment patterns) were used as covariates. BMI was divided
into four categories: < 18.5, 18.5 to < 25, 25 to < 30 and
≥ 30 kg/m2, labelled as underweight, normal weight, over-
weight and obese, respectively. Age was divided into five
categories: 40–54, 55–64, 65–74, 75–84 and ≥ 85 years.
Total cholesterol was defined as high if it was ≥ 5 mmol/l.
The area-based Scottish Index of Multiple Deprivation
(SIMD) 2006 was used as a measure of socio-economic
status, calculating an individual’s relative deprivation based
upon income, employment, health, education, skills and
training, housing, geographic access and crime in the
postcode area of residence [14].
A binary dependent variable was developed from a file
containing patients’ prescription records according to
whether a person had a record of being prescribed a statin
within the 2 years following diagnosis with diabetes.
Statistical analysis
The data used in the analysis were confined to those from
individuals whowere aged over 40 years and newly diagnosed
with diabetes during the study period (1 January 2006 to 1
March 2008), with no recorded history of a hospital admis-
sion with cardiovascular disease or prior statin prescription,
for whom complete data were available, and who did not die
within 6 months of diagnosis (this selection process is
illustrated in Fig. 1). For measures that vary over time, for
example total serum cholesterol, the measurement closest to
the date of diabetes diagnosis was used. The follow-up period
was for 2 years after diagnosis with diabetes.
We conducted sex-stratified logistic regression analysis on
these data, with the reference categories as follows: depriva-
tion = Scottish Index of Multiple Deprivation quintile one
(the most deprived quintile); age = 40–54 years; diabetes
type = Type 2 diabetes; cholesterol < 5 mmol/l; BMI = 18.5
to < 25 kg/m2; and smoking status = never smoked, as
these were either the largest categories in their respective
What’s new?
• This article reports the first use of Scottish Care
Information – Diabetes Collaboration project data to
examine which factors are associated with statin
prescription in people during the first 2 years after
diagnosis with diabetes in Scotland.
• The results suggest that guidelines for the universal use
of statins among people with diabetes were not being
followed during the study period and that, as a result,
opportunities to reduce cardiovascular disease risk were
missed.
• Decision support systems that prompt clinicians of risk
reduction strategies could improve adherence to guide-
lines.
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variables or were the most theoretically sound category to
choose.
All analyses were conducted using Stata 11 (StataCorp.,
College Station, TX, USA).
Results
There were 4622 people with a history of cardiovascular
disease prior to diagnosis of diabetes within the study period,
of whom 92% had a record of statin prescription, and
16 577 people who were already receiving a statin prescrip-
tion for primary prevention of cardiovascular disease when a
diagnosis of diabetes was made. People excluded from the
analysis because they had missing data for one or more
variables had a similar distribution of the other variables,
although there was a lower proportion of current smokers
(24% compared with 45%) among people whose data were
excluded than those whose data were included. The data
selection procedure is summarized in Fig. 1.
There were 7157 men and 5601 women with incident
diabetes between 1 January 2006 and 1 March 2008 who
had no history of cardiovascular disease or previous statin
prescription for whom complete data were available.
Although all of these people were eligible for statin treatment
based on contemporary guidelines, only 68% of men and
69% of women overall had a record of statin prescription in
the 2 years following diagnosis with diabetes. The median
time between diagnosis of diabetes and prescription of statins
was 102 days.
The proportion of people prescribed statins varied by
different characteristics (Table 1). There were higher pro-
portions with a statin prescription record in people in the 55-
to 64-years-of-age category than other age groups, in people
with Type 2 compared with Type 1 diabetes, in people who
were overweight or obese (BMI ≥ 25 kg/m2) compared with
those who are normal or underweight (BMI < 25 kg/m2) and
in current or former smokers than people who have never
smoked, and in people with total cholesterol levels
≥ 5 mmol/l compared with < 5 mmol/l. The proportion
Diagnosed with diabetes
within study period
n = 37 301
Died within 6 months of
diagnosis
n = 485
Lived for over 6
months following diagnosis
n = 36 816
Record of prior
cardiovascular disease
hospital admission
n = 4622
Free from prior
cardiovascular disease
n = 32 194
Record of prior statin
prescription
n = 16 577
No record of prior statin
prescription
n = 15 617
Missing data
n = 2859
Complete data
n = 12 758
FIGURE 1 This data selection flow chart shows the process by which
the study cohort were selected from the diabetes register.
Table 1 Proportion and number of people of over 39 years of age with
no previous history of cardiovascular disease or statin prescription who
had a statin prescription record within 2 years of diagnosis of diabetes
in Scotland 2006–2008 by sex and population subgroup
Men n = 7157 %
(n)
Women n = 5601 %
(n)
Age (years)
40–54 70 (1989) 68 (1181)
55–64 71 (1610) 74 (1204)
65–74 65 (901) 72 (966)
75–84 55 (318) 61 (462)
≥ 85 33 (29) 31 (44)
Diabetes type
Type 1 49 (63) 48 (30)
Type 2 68 (4768) 69 (3813)
BMI (kg/m2)
< 18.5 49 (18) 40 (23)
18.5 to < 25 61 (528) 62 (444)
25 to < 30 68 (1728) 69 (1015)
> 30 69 (2573) 71 (2374)
Smoking status
Never smoked 66 (1863) 67 (1919)
Current smoker 70 (1172) 74 (861)
Former smoker 69 (1812) 69 (1077)
Cholesterol (mmol/l)
< 5 56 (1799) 56 (1149)
≥ 5 77 (3048) 76 (2708)
Scottish Index of Multiple Deprivation quintile
1 (most deprived) 70 (1099) 73 (979)
2 69 (1058) 68 (887)
3 66 (945) 69 (796)
4 65 (896) 65 (627)
5 (least deprived) 69 (849) 67 (568)
Total 68 (4847) 69 (3857)
642
ª 2014 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Statins for primary prevention in people with new diabetes  N. R. V. Jones et al.
receiving statins was highest in the most socio-economically
deprived quintile.
Multivariate analysis
Table 2 shows the results of logistic regression analysis
conducted separately for men and women, with the inclusion
of age, type of diabetes, BMI category, smoking status,
cholesterol level and deprivation quintile as covariates.
Crude and age-adjusted odds were very similar and, as a
consequence, the relationships found between statin pre-
scription and the covariates are very similar to those reported
above. Higher odds of a record of a statin prescription were
found for people in the 55- to 64-years-of-age category
than other age groups, in people who were overweight or
obese (BMI ≥ 25 kg/m2) compared with those who are
normal or underweight (BMI < 25 kg/m2) and in current
or former smokers than people who have never smoked,
with the highest odds ratio noted for people with total
cholesterol levels ≥ 5 mmol/l compared with < 5 mmol/l.
Lower odds of a record of a statin prescription were found
for people with Type 1 diabetes compared with people
with Type 2 diabetes, but small numbers of people with
incident Type 1 diabetes over 40 years of age result in
wide confidence intervals. There was no clear pattern of
statin prescribing with socio-economic status, although
women in the most deprived quintile had higher odds of
having a statin prescription recorded than women in other
quintiles.
Discussion
Although contemporary guidelines recommended that all
people with diabetes should receive statin treatment [8], we
found that 68% of people diagnosed with diabetes between
January 2006 and March 2008, without a record of prior
cardiovascular disease or statin prescription, were prescribed
a statin for primary prevention of cardiovascular disease
within the 2 years following diagnosis of diabetes. Charac-
teristics associated with higher risk of cardiovascular disease
other than age and type of diabetes, including low socio-eco-
nomic status, a high BMI, current smoking status and high
total cholesterol, were associated with increased odds of a
record of statin prescribing. The strongest association was
between statin prescription and having a total cholesterol
level equal to or in excess of 5 mmol/l, which may partly be
an indication of the effectiveness of the Quality of Outcomes
Framework (QOF), because the Quality of Outcomes
Table 2 Odds ratios for statin prescription in the study population derived from a multivariate model containing age, diabetes type, BMI, smoking
status, cholesterol level and deprivation quintile for men and women
Men n = 7157 Nagelkerke’s r2 = 0.096 Women n = 5601 Nagelkerke’s r2 = 0.101
Odds ratio P-value
Confidence interval
Odds ratio P-value
Confidence interval
Lower Upper Lower Upper
Age (years)
40–54 1.00 1.00
55–64 1.11 0.115 0.98 1.26 1.35‡ 0.000 1.15 1.58
65–74 0.87 0.063 0.75 1.01 1.29† 0.002 1.10 1.52
75–84 0.58‡ 0.000 0.48 0.71 0.80* 0.027 0.66 0.98
≥ 85 0.25‡ 0.000 0.15 0.40 0.24‡ 0.000 0.16 0.36
Diabetes type
Type 1 0.42‡ 0.000 0.29 0.61 0.48† 0.006 0.28 0.81
Type 2 1.00 1.00
BMI (kg/m2)
< 18.5 0.52 0.064 0.26 1.04 0.44† 0.005 0.24 0.78
18.5 to < 25 1.00 1.00
25 to < 30 1.23* 0.019 1.03 1.45 1.26* 0.025 1.03 1.53
≥ 30 1.21* 0.026 1.02 1.43 1.19 0.061 0.99 1.44
Smoking status
Never smoked 1.00 1.00
Former smoker 1.21† 0.002 1.07 1.36 1.05 0.526 0.91 1.20
Current smoker 1.15 0.050 1.00 1.32 1.25† 0.007 1.06 1.47
Total cholesterol (mmol/l)
< 5 1.00 1.00
≥ 5 2.60‡ 0.000 2.34 2.89 2.47‡ 0.000 2.19 2.78
Scottish Index of Multiple Deprivation quintile
1 (most deprived) 1.00 1.00
2 1.03 0.738 0.88 1.20 0.78† 0.006 0.66 0.93
3 0.85 0.054 0.73 1.00 0.83* 0.040 0.69 0.99
4 0.85* 0.045 0.72 1.00 0.68‡ 0.000 0.56 0.82
5 (least deprived) 0.99 0.931 0.84 1.18 0.73† 0.002 0.60 0.89
*P < 0.05, †P < 0.01, ‡P < 0.001.
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Framework provides incentives in primary care for prescrib-
ing statins to people with a cholesterol measurement in this
range. However, it should be noted that SIGN guidance
recommends statin prescription in Type 2 diabetes
> 40 years irrespective of cholesterol level [9].
The finding that the odds of treatment were greater in men
and women with a BMI ≥ 25 kg/m2, male former smokers,
female current smokers, people with total cholesterol
≥ 5 mmol/l and people from more deprived areas compared
with relevant reference groups indicates that people at higher
risk of cardiovascular disease within the study population are
more likely to receive a statin prescription than those at
lower risk.
Despite the small numbers involved, the odds of having a
statin prescription recorded for people with Type 1 diabetes
were statistically significantly lower than for people with
Type 2 diabetes. SIGN guidelines covering this period
suggest treatment at a lower risk threshold for patients with
Type 1 diabetes, because of the potential for underestimation
in the current risk assessment methods for these patients.
However, current guidelines state that statins for primary
prevention of cardiovascular disease ‘are recommended’ for
people with Type 2 diabetes and ‘should be considered’ for
people with Type 1 diabetes. If this is not a chance finding, it
may reflect lack of evidence of effectiveness of statins, or
uncertainty about risk of cardiovascular disease among
people with Type 1 diabetes.
There is evidence from several trials, which contained both
people with and without diabetes, that statin treatment can
be beneficial up to 80 years of age [15–17]. Despite this, we
found that men above 65 years of age and women above
75 years of age had lower odds of receiving statins than
younger people, a finding which is consistent with those of
other studies [18–20]. This could be attributable to a variety
of reasons, including co-morbidity, poly-pharmacy, concerns
about side effects or effectiveness of statin treatment in older
people, given that the time taken for the benefits of statin
treatment to accrue could be greater than an individual’s life
expectancy, and recognition of lower relative risks of
mortality associated with diabetes that develops at older
compared with younger ages. This finding contrasts with the
overall pattern observed in these results, because people at
greater absolute cardiovascular disease risk attributable to
higher age had lower odds of a record of statin prescribing,
whereas people with a high cardiovascular disease risk
indicated by the other factors had greater odds of having a
statin prescribing record.
Our finding that there was a non-linear pattern of statin
prescription by socio-economic status is not consistent with
the inverse care law that describes poorer treatment for the
people at highest risk [21]. The finding of greater proportions
of more deprived people receiving treatment with statins is
consistent with a study reporting treatment patterns for both
primary and secondary prevention of cardiovascular disease
among a general population [7].
Although this study has investigated potential undertreat-
ment with statins, it is worth noting that a recent study has
found that some people with diabetes may be overtreated
with statins, receiving an excessive dosage [22]. In future,
this work could be extended to investigate statin doses and
whether this issue is also present in this population.
Comparison with previous studies
A study that used data from across Scotland to examine the
management of coronary heart disease found that, between
1998 and 2001, the most deprived patients (also defined by
quintiles of Scottish Index of Multiple Deprivation) had
lower odds of receiving a statin than the least deprived (odds
ratio 0.7, 95% CI 0.4–1.2) [6]. The population and time
period differ, but it is interesting that this study found a
differing pattern. This may be explained by increasing
awareness of deprivation as a risk factor [23] and the
introduction of the Quality of Outcomes Framework, one of
the aims of which was to reduce health inequalities [24].
These have been associated with a substantial increase in the
quantity of lipid-lowering medication prescribed in Scotland
between 2003 and 2007 [25].
An analysis of statin prescribing in England found that
general practices in more deprived areas were prescribing
statins to a larger proportion of their patients than were
practices in less deprived locations, even after adjustment had
been made for differences in disease prevalence between these
areas, which corresponds with the social gradient reported
here [7]. However, there is great potential for these results to
be attributable to an ecological fallacy because this analysis
was conducted at a practice rather than individual level.
A 2009 study from Norway discovered that, following
adjustment for age, sex and cardiovascular disease risk
factors, people in the highest education category (a proxy for
socio-economic status) were more likely to start using statins
than people in the lowest education category (relative
risk 1.35, 95% CI 1.00–1.81) [26], whilst an investigation
of statin prescription in Italy found that people with an
intermediate education level (of three levels) had higher
prescription rates than people with the lowest education level
(prevalence rate ratio 1.11, 95% CI 1.04–1.19) [27]. Whilst
educational attainment is not strictly comparable with the
more complex index of deprivation used in our study, it is a
common measure of socio-economic status, and these find-
ings indicate that, in these instances, a lower socio-economic
status was associated with less aggressive treatment, which is
the opposite of the socio-economic relationship we found
and is indicative of a more typical form of inequity. Similar
results were found in Denmark in a 2005 paper where men
of a higher socio-economic status were found to have a
greater likelihood of receiving statins than men of a lower
socio-economic status (relative prevalence proportion 1.85,
95% CI 1.17–2.96), whilst the likelihood for women was
not affected by socio-economic status [10].
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In addition to the differences in population, research
question and study design, the findings of research conducted
in other countries are likely to be markedly different given
differences in healthcare systems. Despite this, it is still of
interest to note the variability in statin prescription and that
its relationship with socio-economic status is not consistent
in its direction over time or between different places. It is also
interesting to note that statins are not universally used, even
in clinical trials among people with diabetes and cardiovas-
cular disease (for example, only approximately 75% of
patients in the coronary artery bypass graft arm and 87% of
people in the percutaneous coronary intervention were
prescribed statins after the study procedure in the SYNTAX
trial among patients with three-vessel or left main coronary
artery disease, and only 86–95% of patients were on statins
in the COURAGE trial, which compared optimized medical
therapy with percutaneous revascularization in patients with
stable coronary artery disease [28,29]).
Study strengths
This study draws its data from a population-based data set
containing records for nearly all people with diagnosed
diabetes in Scotland. It is the first to have investigated factors
associated with statin prescribing in relation to contempo-
rary guidelines among people with diabetes in Scotland. The
outcome of interest was ever having received a prescription
after diagnosis of diabetes, so that people who were unable
to tolerate a statin but who ever received a prescription were
included. The limited use of lipid-lowering treatments other
than statins among people with diabetes in Scotland
(approximately 1% of the population with diabetes have a
record of one or more such prescriptions) means that use of
these treatments is unlikely to confound our findings.
Study limitations
A limitation of this study was the lack of information about
non-pharmaceutical attempts to lower risk that may have
been offered, which means that we could not ascertain
whether patients with a lower perceived risk were being
instructed to modify their lifestyle instead of being treated
with statins, rather than simply receiving no treatment
(although it should be noted that this would still not be
suitable treatment according to the Joint British Society or
SIGN guidelines). In addition, we only considered a limited
number of cardiovascular disease risk factors and did not
investigate records of statin prescription in strata of ethnic-
ity, blood pressure, total:HDL cholesterol, albuminuria/
proteinuria and HbA1c values that may also influence statin
prescribing. This study was limited by not being able to
investigate the relationship between clinician, practice or
hospital characteristics and the decision not to prescribe. We
also do not have information about patients who decline to
receive a statin prescription offered by their clinician, which
might affect different population groups, perhaps younger
people, to a greater extent. The lack of data concerning
over-the-counter statin purchases may also be a problem and
have a differential effect by socio-economic status, but, given
that prescribed statins were free for the majority of this
population (people with diabetes treated with medication or
insulin were exempt from all prescription charges in the
study period), this is unlikely to have had a large effect. This
study is also limited by variation between different sets of
clinical guidelines, which means that it may not be appro-
priate to apply a single standard.
Conclusions
Despite contemporary recommendations that all people with
diabetes should be treated with statins, only 68% of people
with incident diabetes in Scotland who had not been taking
statins before diagnosis of diabetes had a record of a first
statin prescription for primary prevention of cardiovascular
disease within 2 years of follow-up. The odds of statin
prescribing varied with patient characteristics, such that
people at higher risk of cardiovascular disease from factors
other than age were more likely to receive statins than those
at lower risk, suggesting that clinical judgement is used in
applying guidelines. However, it is possible that an oppor-
tunity for cardiovascular disease risk reduction using statin
therapy is being missed in some people with diabetes. Finally,
we found no evidence that the pattern of prescribing was
systematically disadvantaging people from more socio-eco-
nomically deprived populations.
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